5,721 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by Headlands Technologies LLC

Headlands Technologies LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,721 shares of the company's stock, valued at approximately $2,365,000.

Several other institutional investors and hedge funds also recently modified their holdings of IDXX. FMR LLC lifted its holdings in IDEXX Laboratories by 3.6% in the 3rd quarter. FMR LLC now owns 290,861 shares of the company's stock worth $146,949,000 after buying an additional 10,017 shares in the last quarter. D.A. Davidson & CO. grew its position in shares of IDEXX Laboratories by 9.5% during the third quarter. D.A. Davidson & CO. now owns 1,629 shares of the company's stock worth $823,000 after buying an additional 142 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth about $341,000. Glenmede Trust Co. NA raised its stake in IDEXX Laboratories by 2.6% during the third quarter. Glenmede Trust Co. NA now owns 1,874 shares of the company's stock valued at $947,000 after buying an additional 48 shares in the last quarter. Finally, Public Sector Pension Investment Board raised its position in shares of IDEXX Laboratories by 16.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,578 shares of the company's stock valued at $1,808,000 after acquiring an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IDXX shares. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley lowered their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Remove Ads

Insiders Place Their Bets

In related news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

IDEXX Laboratories Trading Down 4.1 %

Shares of NASDAQ:IDXX traded down $17.03 during midday trading on Friday, reaching $393.73. The company had a trading volume of 1,635,645 shares, compared to its average volume of 592,302. The company has a fifty day simple moving average of $435.55 and a two-hundred day simple moving average of $440.31. The firm has a market cap of $31.91 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1-year low of $393.50 and a 1-year high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.